It is definitely a key objective that we have to strive for.
We have to create anchor companies. We've been very good as a country at creating a lot of early-stage companies, and as you indicated in your question, many of them are sold off. They go to the large multinational companies.
Part of that is an absolute business strategy that is a reality. You have a small product, one single drug. You recognize that you want to sell it to the world. You need the infrastructure that the large companies provide. You're never going to become a big pharma company overnight, so you will pursue that path.
For others that have platform-like technologies or manufacturing capacity, like Medicago, AbCellera or Repare, they are more likely to be able to stay here in Canada and grow. If we want to get to that, we have to figure out where the gaps are. Some of that is investment capital. It's the talent piece, but there are also some other tax incentives. There are things like patent boxes, which are being used in other jurisdictions, that allow companies to earn money from their innovation but not be taxed at a high rate until they become a commercially profitable company.
Incentives such as that, tax measures such as that, would be really important to keeping some of those companies here.